IRWD
HealthcareIronwood Pharmaceuticals, Inc.
$4.59
+$0.32 (+7.49%)
Jan 5, 2026
Price History (1Y)
Analysis
Ironwood Pharmaceuticals, Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry within the sector of Healthcare. The company's market capitalization stands at $746.69 million, with revenue totaling $338.99 million over the trailing twelve months. The company demonstrates strong financial health, with profitability metrics indicating its ability to maintain a high gross margin of 101.5%, an operating margin of 63.6%, and a profit margin of 8.4%. Additionally, Ironwood's return on assets is notable at 22.9%, although the return on equity is not available. The company's balance sheet shows a current ratio of 1.13, suggesting its ability to meet short-term obligations. With $140.41 million in cash and $598.24 million in debt, Ironwood's financial position appears stable. Valuation metrics for Ironwood Pharmaceuticals indicate a price-to-earnings ratio (TTM) of 25.50, with forward P/E at 5.38. The company has experienced significant revenue growth over the year-on-year period, with a rate of 33.3%. However, earnings growth is even more pronounced at 1046.8%, although dividend yield and payout ratio are not available for consideration.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $746.69M
- P/E Ratio
- 25.50
- 52-Week High
- $5.78
- 52-Week Low
- $0.53
- Avg Volume
- 3.78M
- Beta
- 0.19
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 253